← United States · Coverage record
US · SEC FORM 4
Salarius Pharmaceuticals, Inc.
SLRX · Nasdaq · CIK 0001615219 · Healthcare
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
10 Form 4 transaction lines observed in the same window
0 sales · 10 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
Showing the six most active owners; 4 additional owner(s) remain in Form 4 evidence.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-11-20 · HANISH ARNOLD C.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
The FINRA report lists no short interest for this ticker.
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-11-20 | HANISH ARNOLD C | Purchase (P) | Common Stock | 5,000 | USD 0.75 | USD 3,750 | SEC filing ↗ |
| 2025-11-20 | Rosenblum Mark J | Purchase (P) | Common Stock | 20,000 | USD 0.80 | USD 16,000 | SEC filing ↗ |
| 2022-06-07 | Lieber Jonathan I | Purchase (P) | Common Stock | 37,500 | USD 0.19 | USD 7,125 | SEC filing ↗ |
| 2022-06-07 | Burleson Tess | Purchase (P) | Common Stock | 27,700 | USD 0.18 | USD 4,986 | SEC filing ↗ |
| 2022-06-06 | McVicar William K. | Purchase (P) | Common Stock | 26,553 | USD 0.19 | USD 5,045 | SEC filing ↗ |
| 2022-06-03 | HANISH ARNOLD C | Purchase (P) | Common Stock | 28,000 | USD 0.18 | USD 5,040 | SEC filing ↗ |
| 2022-05-31 | Rosenblum Mark J | Purchase (P) | Common Stock | 28,000 | USD 0.18 | USD 5,040 | SEC filing ↗ |
| 2022-05-26 | Arthur David J. | Purchase (P) | Common Stock | 43,900 | USD 0.18 | USD 7,902 | SEC filing ↗ |
| 2022-03-03 | Rosenblum Mark J | Purchase (P) | Common Stock | 76,246 | USD 0.39 | USD 29,736 | SEC filing ↗ |
| 2022-03-03 | Arthur David J. | Purchase (P) | Common Stock | 139,488 | USD 0.39 | USD 54,400 | SEC filing ↗ |
| 2021-08-17 | Arthur David J. | Purchase (P) | Common Stock | 4,000 | USD 0.90 | USD 3,580 | SEC filing ↗ |
| 2021-08-10 | HANISH ARNOLD C | Purchase (P) | Common Stock | 7,000 | USD 0.88 | USD 6,160 | SEC filing ↗ |
| 2020-08-21 | HANISH ARNOLD C | Purchase (P) | Common Stock | 4,000 | USD 0.98 | USD 3,920 | SEC filing ↗ |
| 2020-08-21 | HANISH ARNOLD C | Purchase (P) | Common Stock | 4,000 | USD 0.98 | USD 3,920 | SEC filing ↗ |
| 2020-08-19 | Arthur David J. | Purchase (P) | Common Stock | 1,000 | USD 1.01 | USD 1,010 | SEC filing ↗ |
Form 4 evidence
14 transaction lines in the latest 365-day window; 67 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-08-31 | Rosenblum Mark J | Award / grant (A) | Common Stock | 9,682 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-31 | PIERCE FREDERICK II | Award / grant (A) | Common Stock | 33,455 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-31 | McVicar William K. | Award / grant (A) | Common Stock | 3,000 | USD 0.00 | USD 0 | SEC filing ↗ |
Show recent Form 4 evidence (13 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-08-31 | Rosenblum Mark J | Award / grant (A) | Common Stock | 9,682 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-31 | PIERCE FREDERICK II | Award / grant (A) | Common Stock | 33,455 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-31 | McVicar William K. | Award / grant (A) | Common Stock | 3,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-31 | Marschel Peter Klaus | Award / grant (A) | Common Stock | 3,900 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-31 | Lieber Jonathan I | Award / grant (A) | Common Stock | 2,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-31 | Lammers Paul | Award / grant (A) | Common Stock | 2,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-31 | Hibner Barbara Louise | Award / grant (A) | Common Stock | 4,216 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-31 | HANISH ARNOLD C | Award / grant (A) | Common Stock | 3,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-31 | Gauthier Patricia G. | Award / grant (A) | Common Stock | 2,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-31 | Burleson Tess | Award / grant (A) | Common Stock | 2,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-30 | HANISH ARNOLD C | Sale (S) | Common Stock | 27 | USD 0.64 | USD 17 | SEC filing ↗ |
| 2025-11-20 | HANISH ARNOLD C | Purchase (P) | Common Stock | 5,000 | USD 0.75 | USD 3,750 | SEC filing ↗ |
| 2025-11-20 | Rosenblum Mark J | Purchase (P) | Common Stock | 20,000 | USD 0.80 | USD 16,000 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-19 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | SLRX |
| CIK | 0001615219 |
| Sector | Healthcare |
| Industry | — Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 67 transaction lines from 2020-02-11 to 2026-08-31 31 P purchase lines · 2 S sale lines · 34 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.